Phio Pharmaceuticals Corp./$PHIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Ticker
$PHIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
5
Website
PHIO Metrics
BasicAdvanced
$12M
-
-$9.41
0.85
-
Price and volume
Market cap
$12M
Beta
0.85
52-week high
$3.48
52-week low
$0.97
Average daily volume
1.8M
Financial strength
Current ratio
10.58
Quick ratio
10.455
Profitability
EBITDA (TTM)
-7.049
Management effectiveness
Return on assets (TTM)
-43.43%
Return on equity (TTM)
-76.12%
Valuation
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-0.274
Free cash flow yield (TTM)
-364.98%
Free cash flow per share (TTM)
-8.869
Growth
Earnings per share change (TTM)
34.82%
3-year earnings per share growth (CAGR)
-54.49%
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Newsfile Corp·6 days ago
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Newsfile Corp·6 days ago
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Newsfile Corp·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phio Pharmaceuticals Corp. stock?
Phio Pharmaceuticals Corp. (PHIO) has a market cap of $12M as of July 31, 2025.
What is the P/E ratio for Phio Pharmaceuticals Corp. stock?
The price to earnings (P/E) ratio for Phio Pharmaceuticals Corp. (PHIO) stock is 0 as of July 31, 2025.
Does Phio Pharmaceuticals Corp. stock pay dividends?
No, Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders as of July 31, 2025.
When is the next Phio Pharmaceuticals Corp. dividend payment date?
Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. (PHIO) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.